NEW YORK (GenomeWeb) - Veracyte announced after the close of the market Thursday that revenues for its second quarter rose 37 percent year over year on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended June 30, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased 37 percent to $11.9 million from $8.7 million a year ago, missing the average Wall Street expectation of $12.2 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.